Related Experiment Videos
Multimodality therapy for advanced and recurrent vulvar squamous cell carcinoma. A pilot project
L F Carson1, L B Twiggs, L L Adcock
1Women's Cancer Center, Minneapolis, MN.
The Journal of Reproductive Medicine
|November 1, 1990
Summary
This study evaluated a combination chemotherapy regimen plus radiotherapy for advanced vulvar carcinoma. The multimodality treatment showed a 33% overall survival rate, suggesting its consideration for extensive or resistant cases.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Radiation Oncology
Background:
- Advanced or recurrent vulvar carcinoma presents a significant treatment challenge.
- Limited effective therapeutic options exist for extensive or resistant vulvar cancer.
Purpose of the Study:
- To assess the efficacy and safety of a neoadjuvant chemotherapy regimen combined with radiotherapy for advanced or recurrent vulvar carcinoma.
- To evaluate treatment outcomes including response rates, operative morbidity, and survival.
Main Methods:
- Eight women with advanced/recurrent vulvar carcinoma received 5-fluorouracil, mitomycin C, and cisplatin concurrently with radiotherapy.
- Posttreatment radical vulvectomy was performed in five patients.
- Clinical response and survival were monitored.
Main Results:
- Six out of eight patients achieved a complete clinical response.
- Five patients undergoing radical vulvectomy experienced acceptable operative morbidity.
- The overall survival rate at 27 months was 33%.
- One patient progressed on therapy, one death was due to chemotherapy toxicity, and two died of intercurrent disease.
Conclusions:
- A multimodality approach combining chemotherapy (5-fluorouracil, mitomycin C, cisplatin) with radiotherapy is a viable option for advanced or recurrent vulvar carcinoma.
- This treatment strategy warrants consideration for patients with extensive or resistant disease.